Filing Details

Accession Number:
0000950170-23-038268
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-03 20:01:15
Reporting Period:
2023-08-01
Accepted Time:
2023-08-03 20:01:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1693011 Inozyme Pharma Inc. INZY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1551966 Lorne Robert Hopfner C/O Inozyme Pharma, Inc.
321 Summer Street Suite 400
Boston MA 02210
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-01 119,048 $4.80 2,923,110 No 4 P Indirect By Pivotal
Common Stock Acquisiton 2023-08-01 714,285 $4.80 1,571,741 No 4 P Indirect By Pivotal
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Pivotal
No 4 P Indirect By Pivotal
Footnotes
  1. Held directly by Pivotal bioVenture Partners Fund I, L.P.
  2. The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
  3. Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
  4. Held directly by Pivotal bioVenture Partners Fund II, L.P.